Clinical trial · Interventional
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
Phase II Study of Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
NCT02717091CI-TRIAL-00047094unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Borderline Resectable Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FOLFIRINOX | Drug | — | UNRESOLVED |
| gemcitabine + nab-paclitaxel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- FOLFIRINOX
- description
- 4 course of FILFIRINOX before surgery
- interventionNames
- Drug: FOLFIRINOX
- type
- EXPERIMENTAL
- label
- GEM + nab-PTX
- description
- 2 course of GEM + nab-PTX before surgery
- interventionNames
- Drug: gemcitabine + nab-paclitaxel
Primary outcomes (1)
- measure
- R0 resection rate
- timeFrame
- 3 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Borderline resectable pancreatic cancer (based on NCCN guideline version 2.2015) 2. first treatment for pancreatic cancer 3. performance status 0 or 1 4. adequate one marrow function 5. adequate renal function 6. obtained informed consent Exclusion Criteria: 1. other active concomitant malignancies 2. other severe medical conditions; contraindication of FOLFIRINOX, paclitaxel and gemcitabine 3. pregnant women 4. no informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.